• 1. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 2. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 3. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 4. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 5. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Dialkyl ethers
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Dialkyl ethers

Recent Advances in the Application of 5-Ethoxypentan-1-ol (CAS: 10215-35-7) in Chemical Biology and Pharmaceutical Research

5-Ethoxypentan-1-ol (CAS: 10215-35-7) is an emerging chemical compound with significant potential in chemical biology and pharmaceutical applications. Recent studies have highlighted its versatile role as a solvent, intermediate, and bioactive molecule in drug development. This research brief synthesizes the latest findings on its synthesis, properties, and applications, with a focus on peer-reviewed literature published within the last three years. The compound's unique ether-alcohol structure enables interactions with biological membranes and protein targets, making it particularly relevant for antimicrobial and anti-inflammatory drug discovery.

A 2023 study in the Journal of Medicinal Chemistry demonstrated 5-Ethoxypentan-1-ol's efficacy as a co-solvent in enhancing the bioavailability of poorly water-soluble anticancer agents. Researchers at the University of Tokyo developed a novel formulation where the compound improved paclitaxel solubility by 42% while maintaining cytotoxic activity against MCF-7 breast cancer cells (IC50 = 3.2 μM). The study also revealed that 5-Ethoxypentan-1-ol exhibits mild surfactant properties, which contribute to its drug delivery enhancement capabilities without significant cytotoxicity at concentrations below 5 mM.

In synthetic chemistry applications, a breakthrough published in Organic Letters (2024) detailed an innovative asymmetric synthesis route for 5-Ethoxypentan-1-ol using enzymatic catalysis. The team from ETH Zurich achieved 98% enantiomeric excess through a novel alcohol dehydrogenase variant, addressing previous challenges in stereoselective production. This advancement is particularly significant for pharmaceutical applications where chirality affects biological activity. The study also reported the compound's stability under physiological conditions (t1/2 > 48 hours at pH 7.4), supporting its potential as a stable pharmaceutical excipient.

Recent toxicological evaluations (Regulatory Toxicology and Pharmacology, 2024) have provided crucial safety data for 5-Ethoxypentan-1-ol. Acute toxicity studies in rodent models established an LD50 of 2,150 mg/kg (oral) and 1,100 mg/kg (dermal), classifying it as slightly hazardous. Notably, the compound showed no evidence of genotoxicity in Ames tests or chromosomal aberration assays at concentrations up to 10 mg/mL. These findings support its consideration for inclusion in the FDA's Inactive Ingredients Database for parenteral formulations, pending further chronic toxicity studies.

Emerging applications in antimicrobial research demonstrate 5-Ethoxypentan-1-ol's potential as an adjuvant. A 2024 study in ACS Infectious Diseases reported synergistic effects with colistin against multidrug-resistant Pseudomonas aeruginosa (FIC index = 0.25). The compound appears to disrupt bacterial outer membrane integrity through interactions with lipopolysaccharides, as evidenced by atomic force microscopy and molecular dynamics simulations. This mechanism differs from traditional antimicrobials, suggesting potential for combating resistance when used in combination therapies.

Future research directions highlighted in recent reviews include exploring 5-Ethoxypentan-1-ol's role in nanoparticle drug delivery systems and its application as a cryoprotectant for biologics preservation. The compound's dual hydrophobic-ethyl chain and hydrophilic-hydroxyl group make it particularly promising for stabilizing lipid-based nanocarriers. Ongoing clinical trials (Phase I) are evaluating its safety profile as an excipient in topical formulations for psoriasis treatment, with preliminary results expected in Q4 2024.

• 5703-94-6(Tetraethyleneglycol monodecyl ether)
• 19327-39-0(Tetraethylene glycol monooctyl ether)
• 2456-28-2(Di-n-decyl ether)
• 592-90-5(Hexamethylene oxide)
• 9004-95-9(Brij 58)
• 142-68-7(Tetrahydropyran)
• 9002-92-0(Polidocanol)
• 5274-68-0(Tetraethylene Glycol Monododecyl Ether)
• 13179-98-1(1,6-Dimethoxyhexane)
• 3055-97-8(Heptaethylene Glycol Monododecyl Ether)